Skip to main content

LambdaVision

ApplicationFarmington, CT, USAFounded 2009· One of 381 Application companies tracked by AMPulse

Develops a protein-based artificial retina using a layer-by-layer additive manufacturing process in microgravity to restore vision for patients with retinal degenerative diseases like retinitis pigmentosa and age-related macular degeneration.

CEO / Founder
Nicole Wagner
Team Size
11-50
Stage
Active
Total Funding
$22.0M
Latest Round
Seed
Key Investors
Seven Seven Six; Aurelia Foundry Fund; Seraphim Space; Boryung; E2MC Ventures; Connecticut Innovations; NASA; National Science Foundation (NSF); National Eye Institute

Technology & Products

Key Products

Protein-based artificial retina

Technological Advantage

Proprietary layer-by-layer manufacturing process for protein-polymer thin films, optimized in microgravity to achieve superior homogeneity and performance; patent-protected technology with a worldwide patent application allowed by USPTO.

Differentiation

Value Proposition

Offers a novel treatment that restores functional sight where no cure exists, leveraging microgravity manufacturing to produce highly uniform protein thin films that improve device performance and reliability.

How They Differentiate

Unique protein-based approach using bacteriorhodopsin vs. electronic retinal implants; microgravity-enabled manufacturing for enhanced layer uniformity and performance, with 9 successful ISS missions validating the process.

Market & Competition

Target Customers

Patients with advanced retinal degenerative diseases (RP, AMD), ophthalmologists, medical institutions

Industry Verticals

Medical; Biotechnology

Competitors

Pixium Vision; Bionic Vision Technologies

Growth & Milestones

Growth Metrics

Secured over $17M in non-dilutive funding from NASA, NSF, and National Eye Institute; completed 9 ISS missions; plans to initiate clinical trials for RP within 3 years.

Major Milestones

Founded in 2009; $5M NASA award in 2020 for ISS development; 9 successful ISS missions; $7M seed round closed in 2025; Partnership with Starlab Space for commercial LEO manufacturing in 2026

Notable Customers

Space Tango; Starlab Space LLC; Voyager Technologies

https://www.lambdavision.com

Why this company matters

LambdaVision occupies a distinct niche at the intersection of advanced bioprinting and space-based manufacturing. The company's core proposition is a protein-based artificial retina designed to restore functional vision where no cure exists, differentiating from competitors like Pixium Vision and Bionic Vision Technologies that rely on electronic retinal implants. Its approach centers on bacteriorhodopsin, a light-activated protein, instead of silicon-based electronics.

The company's technological advantage stems from its proprietary layer-by-layer additive manufacturing process for creating protein-polymer thin films. This process is specifically optimized for the microgravity environment of the International Space Station, which mitigates the effects of gravity-driven convection and sedimentation. The result is a device with superior layer uniformity and homogeneity, which is critical for performance and reliability. The company has validated this approach through nine successful ISS missions.

LambdaVision targets patients with advanced retinal degenerative diseases such as retinitis pigmentosa and age-related macular degeneration. Its development is supported by key partnerships with space infrastructure providers like Space Tango and Starlab Space LLC, as well as NASA and academic institutions. The company plans to initiate clinical trials for retinitis pigmentosa within three years.

The company's strategic moat is built on its unique microgravity manufacturing process and the associated IP, which has received a Notice of Allowance from the USPTO. However, its position carries inherent risks related to the cost, scalability, and regulatory pathway for a space-manufactured medical device. Success hinges on translating its technical achievements from low-Earth orbit into a commercially viable and clinically approved therapeutic.